{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:25:10Z","timestamp":1761197110775},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,8]]},"DOI":"10.1212\/wnl.47.2.417","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:22:30Z","timestamp":1336915350000},"page":"417-424","update-policy":"http:\/\/dx.doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["Multiple cerebral lesions complicating therapy with interleukin-2"],"prefix":"10.1212","volume":"47","author":[{"given":"B. Illowsk","family":"Karp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Khorsand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Merigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","first-page":"4","volume":"210","year":"1989","unstructured":"Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.","journal-title":"Ann Surg"},{"key":"e_1_3_1_3_2","first-page":"2","volume":"20","year":"1994","unstructured":"Vlasveld LT, Rankin EM. Recombinant interleukin-2 in cancer: basic and clinical aspects. Cancer Treat Rev 1994;20:275-311.","journal-title":"Cancer Treat Rev"},{"key":"e_1_3_1_4_2","first-page":"2","volume":"61","year":"1994","unstructured":"Oldham RK. Therapy with interleukin-2 and tumor-derived activated lymphocytes. Immunol Ser 1994;61:251-271.","journal-title":"Immunol Ser"},{"key":"e_1_3_1_5_2","first-page":"1","volume":"8","year":"1994","unstructured":"Klimas N, Patarca R, Walling J, et al. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 1994;8:1073-1081.","journal-title":"AIDS"},{"key":"e_1_3_1_6_2","first-page":"5","volume":"332","year":"1995","unstructured":"Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995;332:567-575.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_7_2","first-page":"2","volume":"11","year":"1993","unstructured":"Bukowski RM, Young J, Goodman G, et al. Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs 1993;11:211-217.","journal-title":"Invest New Drugs"},{"key":"e_1_3_1_8_2","first-page":"6","volume":"14","year":"1988","unstructured":"Sculier JP, Bron D, Verboven N, Klastersky J. Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Med 1988;14:666-667.","journal-title":"Intensive Care Med"},{"key":"e_1_3_1_9_2","first-page":"3","volume":"594","year":"1990","unstructured":"Triozzi PL, Kinney P, Rinehart JJ. Central nervous system toxicity of biological response modifiers. Ann NY Acad Sci 1990;594:347-354.","journal-title":"Ann NY Acad Sci"},{"key":"e_1_3_1_10_2","first-page":"2","volume":"107","year":"1987","unstructured":"Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300.","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_11_2","first-page":"1","volume":"8","year":"1994","unstructured":"Forman AD. Neurologic complications of cytokine therapy. Oncology 1994;8:105-110.","journal-title":"Oncology"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.1"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Philip T Mercatello A Negrier S et al. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev 1989;16(suppl A):91-104.","DOI":"10.1016\/0305-7372(89)90028-5"},{"key":"e_1_3_1_14_2","first-page":"4","volume":"42","year":"1992","unstructured":"Loh FL, Herskovitz S, Berger AR, Swerdlow ML. Brachial plexopathy associated with interleukin-2 therapy. Neurology 1992;42:462-463.","journal-title":"Neurology"},{"key":"e_1_3_1_15_2","first-page":"5","volume":"68","year":"1992","unstructured":"Heys SD, Mills KLG, Eremin O. Bilateral carpal tunnel syndrome associated with interleukin-2 therapy. Postgrad Med J 1992;68:587-588.","journal-title":"Postgrad Med J"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80758-7"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007053230101"},{"key":"e_1_3_1_18_2","first-page":"5","volume":"167","year":"1993","unstructured":"Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I\/II study. J Infect Dis 1993;167:519-525.","journal-title":"J Infect Dis"},{"key":"e_1_3_1_19_2","first-page":"4","volume":"177","year":"1993","unstructured":"Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993;177:483-492.","journal-title":"J Exp Med"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.1.1"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.1.1"},{"key":"e_1_3_1_22_2","first-page":"2","volume":"14","year":"1993","unstructured":"Lazzarino LG, Nicolai A, Cavallaro T, Rizzuto N. Neurotoxicity of idiopathic hypereosinophilia on a case with simultaneous CNS and PNS involvement. Ital J Neurol Sci 1993;14:259-262.","journal-title":"Ital J Neurol Sci"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-1-"},{"key":"e_1_3_1_24_2","first-page":"2","volume":"15","year":"1993","unstructured":"Meyers CA, Yung WKA. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol 1993;15:265-267.","journal-title":"J Neurooncol"},{"key":"e_1_3_1_25_2","first-page":"2","volume":"69","year":"1988","unstructured":"Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 1988;69:29-34.","journal-title":"J Neurosurg"},{"key":"e_1_3_1_26_2","first-page":"2","volume":"498","year":"1989","unstructured":"Araujo DM, Lapchak PA, Collier B, Quirion R. Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in rat brain: interaction with the cholinergic system. Brain Res 1989;498:257-266.","journal-title":"Brain Res"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(88)90260-1"},{"key":"e_1_3_1_28_2","first-page":"6","volume":"59","year":"1991","unstructured":"DeSarro G, Nistico G. Effects of pertussis toxin, dibutyrylcyclic-AMP, bromo-cyclic-AMP and forskolin on the behavioural and electrocortical power spectrum changes induced by microinfusion of interleukin-2 into the locus coeruleus. Int J Neurosci 1991;59:67-79.","journal-title":"Int J Neurosci"},{"key":"e_1_3_1_29_2","first-page":"4","volume":"643","year":"1994","unstructured":"Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2, and -6. Brain Res 1994;643:40-49.","journal-title":"Brain Res"},{"key":"e_1_3_1_30_2","first-page":"3","volume":"13","year":"1993","unstructured":"Hanisch U, Seto D, Quirion R. Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 1993;13:3368-3374.","journal-title":"J Neurosci"},{"key":"e_1_3_1_31_2","first-page":"2","volume":"591","year":"1992","unstructured":"Nemni R, Iannaccone S, Quattrini A, et al. Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res 1992;591:248-252.","journal-title":"Brain Res"},{"key":"e_1_3_1_32_2","first-page":"6","volume":"321","year":"1986","unstructured":"Benveniste EN, Merrill JE. Stimulation of oligodendroglial proliferation and maturation by interleukin-2. Nature 1986;321:610-613.","journal-title":"Nature"},{"key":"e_1_3_1_33_2","first-page":"5","volume":"47","year":"1987","unstructured":"Ellison MD, Povlishock JT, Merchant RE. Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 1987;47:5765-5770.","journal-title":"Cancer Res"},{"key":"e_1_3_1_34_2","first-page":"1","volume":"261","year":"1993","unstructured":"Eitan S, Schwartz M. A transglutaminase that converts interleukin-2 into a factor cytotoxic to oligodendrocytes. Science 1993;261:106-108.","journal-title":"Science"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.1.1"},{"key":"e_1_3_1_36_2","first-page":"3","volume":"496","year":"1989","unstructured":"Kobiler D, Lustig S, Gozes Y, Ben-Nathan D, Akov Y. Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain. Brain Res 1989;496:314-316.","journal-title":"Brain Res"},{"key":"e_1_3_1_37_2","first-page":"6","volume":"14","year":"1992","unstructured":"Banks WA, Kastin AJ. The interleukins-1a, -1b, and -2 do not acutely disrupt the murine blood-brain barrier. Int J Immunopharmacol 1992;14:629-636.","journal-title":"Int J Immunopharmacol"},{"key":"e_1_3_1_38_2","first-page":"2","volume":"33","year":"1991","unstructured":"Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 1991;33:245-251.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.1.4"},{"key":"e_1_3_1_40_2","first-page":"3","volume":"6","year":"1988","unstructured":"Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344-350.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_41_2","first-page":"6","volume":"9","year":"1991","unstructured":"Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_42_2","first-page":"8","volume":"88","year":"1994","unstructured":"Oleksowicz L, Strack M, Dutcher JP, et al. A distinct coagulopathy associated with interleukin-2 therapy. Br J Haematol 1994;88:892-894.","journal-title":"Br J Haematol"},{"key":"e_1_3_1_43_2","first-page":"3","volume":"47","year":"1981","unstructured":"Byrd RL, Rohrbaugh TM, Raney RB, Norris DG. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981;47:37-40.","journal-title":"Cancer"},{"key":"e_1_3_1_44_2","first-page":"1","volume":"12","year":"1988","unstructured":"Rippe DJ, Edwards MK, Schrodt JF, Bognanno JR, D'Amour PG, Boyko OB. Reversible cerebral lesions associated with tiazofurin usage: MR demonstration. J Comput Assist Tomogr 1988;12:1078-1081.","journal-title":"J Comput Assist Tomogr"},{"key":"e_1_3_1_45_2","first-page":"1","volume":"6","year":"1990","unstructured":"Ghalie R, Fitzsimmons WE, Bennett D, Kaizer H. Cortical blindness: a rare complication of cyclosporine therapy. Bone Marrow Transplant 1990;6:147-149.","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_1_46_2","first-page":"2","volume":"49","year":"1990","unstructured":"Scheinman SJ, Reinitz ER, Petro G, Schwartz RA, Szmalc FS. Cyclosporine central neurotoxicity following renal transplantation. Transplantation 1990;49:215-216.","journal-title":"Transplantation"},{"key":"e_1_3_1_47_2","first-page":"8","volume":"16","year":"1992","unstructured":"Patronas NJ, Argyropoulou M. Intravascular thrombosis as a possible cause of transient cortical brain lesions: CT and MRI. J Comput Assist Tomogr 1992;16:849-855.","journal-title":"J Comput Assist Tomogr"},{"key":"e_1_3_1_48_2","first-page":"3","volume":"13","year":"1984","unstructured":"Liebowitz HA, Hall PE. Cortical blindness as a complication of eclampsia. Ann Emerg Med 1984;13:365-367.","journal-title":"Ann Emerg Med"},{"key":"e_1_3_1_49_2","first-page":"3","volume":"13","year":"1993","unstructured":"Marra TR, Shah M, Mikus MA. Transient cortical blindness due to hypertensive encephalopathy: magnetic resonance imaging correlation. J Clin Neuroophthalmol 1993;13:35-37.","journal-title":"J Clin Neuroophthalmol"},{"key":"e_1_3_1_50_2","first-page":"3","volume":"29","year":"1992","unstructured":"Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness. Cancer Chemother Pharmacol 1992;29:329-330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_1_51_2","first-page":"1","volume":"29","year":"1993","unstructured":"VanGelder T, Geurs P, Kho GS, Dippel DWJ, Vecht CJ, Splinter TAW. Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur J Cancer 1993;29A:1497-1498.","journal-title":"Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur J Cancer"},{"key":"e_1_3_1_52_2","first-page":"1","volume":"20","year":"1992","unstructured":"Highley M, Meller ST, Pinkerton CR. Seizures and cortical dysfunction following high-dose cisplatin administration in children. Med Pediatr Oncol 1992;20:143-148.","journal-title":"Med Pediatr Oncol"},{"key":"e_1_3_1_53_2","first-page":"1","volume":"45","year":"1988","unstructured":"Hauser RA, Lacey DM, Knight MR. Hypertensive encephalopathy: magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol 1988;45:1078-1083.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_54_2","first-page":"2","volume":"14","year":"1990","unstructured":"Heran F, Defer G, Brugieres P, Brenot F, Gaston A, Degos J-D. Cortical blindness during chemotherapy: clinical, CT, and MR correlations J Comput Assist Tomogr 1990;14:262-266.","journal-title":"Cortical blindness during chemotherapy: clinical, CT, and MR correlations J Comput Assist Tomogr"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.47.2.417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:19:48Z","timestamp":1711534788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.47.2.417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1996,8]]}},"alternative-id":["10.1212\/WNL.47.2.417"],"URL":"https:\/\/doi.org\/10.1212\/wnl.47.2.417","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,8]]}}}